Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Valeant Pharmaceuticals Intl (VRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,501,657
  • Shares Outstanding, K 348,590
  • Annual Sales, $ 9,674 M
  • Annual Income, $ -2,409,000 K
  • 36-Month Beta -0.22
  • Price/Sales 0.84
  • Price/Cash Flow 1.57
  • Price/Book 1.42

Price Performance

See More
Period Period Low Period High Performance
1-Month
20.71 +6.37%
on 12/28/17
24.43 -9.82%
on 01/05/18
+0.48 (+2.23%)
since 12/22/17
3-Month
10.94 +101.37%
on 11/02/17
24.43 -9.82%
on 01/05/18
+9.90 (+81.62%)
since 10/20/17
52-Week
8.31 +165.10%
on 04/24/17
24.43 -9.82%
on 01/05/18
+7.30 (+49.56%)
since 01/20/17

Most Recent Stories

More News
Ortho Dermatologics Announces U.S. FDA Filing Acceptance For IDP-121 Acne Treatment In Lotion Form

PDUFA Date Is Aug. 27, 2018

VRX.TO : 27.45 (+1.97%)
VRX : 22.03 (+2.37%)
Today's Research Reports on Trending Tickers: Sarepta Therapeutics and Valeant Pharmaceuticals

NEW YORK, NY / ACCESSWIRE / January 11, 2018 / All three major indexes dropped Wednesday on news that China is considering halting the purchases of U.S. sovereign debt, with the S&P 500 and Nasdaq logging...

SRPT : 65.65 (+5.24%)
VRX : 22.03 (+2.37%)
Valeant Provides Company Update At The 36th Annual J.P. Morgan Healthcare Conference

Seven Key Products Are Projected to Generate $1 Billion in Sales in 5 Years

VRX.TO : 27.45 (+1.97%)
JPM : 114.33 (+1.17%)
VRX : 22.03 (+2.37%)
Today's Research Reports on Stocks to Watch: Sarepta Therapeutics and Valeant Pharmaceuticals

NEW YORK, NY / ACCESSWIRE / January 8, 2018 / Shares of Sarepta Therapeutics fell over 5% this past Friday. It was revealed that the company's former CEO is now heading a new local start up called Stoke...

SRPT : 65.65 (+5.24%)
VRX : 22.03 (+2.37%)
Bausch + Lomb Receives CE Mark From The European Commission For The Stellaris Elite(TM) Vision Enhancement System, Including The Vitesse(TM) Vitrectomy System

Next-Generation Ophthalmic Surgical Platform Now Available Across Greater Europe

VRX.TO : 27.45 (+1.97%)
VRX : 22.03 (+2.37%)
Valeant Pays Down $300 Million Of Senior Secured Term Loans

Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant" or the "Company") today announced it has paid down an additional $300 million of its senior secured term loans, using cash...

VRX.TO : 27.45 (+1.97%)
VRX : 22.03 (+2.37%)
Valeant To Present At The 36th Annual J.P. Morgan Healthcare Conference

Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant") today announced that Joseph C. Papa, chairman and chief executive officer, is scheduled to present at the 36th Annual J.P....

VRX.TO : 27.45 (+1.97%)
JPM : 114.33 (+1.17%)
VRX : 22.03 (+2.37%)
Valeant (VRX) to Settle Allergan Litigation for $290 Million

Valeant (VRX) and Pershing Square decided to resolve the claims of the long standing Allergan lawsuit for $290 million. Valeant will now pay 33% of the costs, down from the previous agreement of 60%.

SCMP : 17.90 (-0.28%)
AGN : 188.15 (+3.76%)
EXEL : 29.44 (+5.14%)
VRX : 22.03 (+2.37%)
Valeant Announces Preliminary Resolution Of Allergan Shareholder Securities Litigation

Valeant Will Pay $96.25 Million to Resolve the Litigation

VRX.TO : 27.45 (+1.97%)
AGN : 188.15 (+3.76%)
VRX : 22.03 (+2.37%)
Mallinckrodt to Buy Sucampo for $1.2B to Diversify Portfolio

Mallinckrodt (MNK) is all set to acquire Sucampo Pharmaceuticals to diversify its portfolio and counter the decline in sales of its largest drug, Acthar.

SCMP : 17.90 (-0.28%)
PX : 160.62 (-0.78%)
MNK : 21.81 (+2.39%)
VRX : 22.03 (+2.37%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Valeant Pharmaceuticals International, Inc. is a pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics. The Company produces medicines that meet the special health problems of patients....

See More

Key Turning Points

2nd Resistance Point 22.57
1st Resistance Point 22.30
Last Price 22.03
1st Support Level 21.54
2nd Support Level 21.05

See More

52-Week High 24.43
Last Price 22.03
Fibonacci 61.8% 18.27
Fibonacci 50% 16.37
Fibonacci 38.2% 14.47
52-Week Low 8.31

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.